Kymera Therapeutics outlines 2026 clinical trial plans
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
January 13, 2026 7:00 AM ESTKT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027
KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027
KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26
Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026
Well-capitalized with $1.6 billion1 in cash and runway into 2029
Kymera to present its 2026 objectives at the... More
